(Q33974396)

30 July 2017

1 reference

title

Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics (English)

1 reference

30 July 2017

0 references

Sahu A

1

1 reference

PubMed ID

10904113

30 July 2017

Lambris JD

series ordinal

2

1 reference

30 July 2017

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

49

1 reference

30 July 2017

1-2

1 reference

30 July 2017

133-148

1 reference

Enhanced local production of complement components in the small intestines of patients with Crohn's disease

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice. A novel means of protection from complement-mediated injury

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Hemodialysis leukopenia and complement function with different dialyzers

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Molecular cloning and characterization of the human anaphylatoxin C3a receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

C1 INH concentrate in the therapy of hereditary angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Derivation of RNA aptamer inhibitors of human complement C5.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Complement inhibition by FUT-175 and K76-COOH in a pig-to-human lung xenotransplant model.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Production of human antibody repertoires in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The role of complement in experimental disease models

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Complement and the direct mediation of immune glomerular injury: a new perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The complement system in xenotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Policing the membrane: cell surface proteins which regulate complement

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Prolongation of ex vivo–perfused pig xenograft survival by the complement inhibitor compstatin

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-CS antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

C1-esterase inhibitor substitution in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Anaphylatoxin Generation in Multisystem Organ Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

L-156,602, a C5a antagonist with a novel cyclic hexadepsipeptide structure from Streptomyces sp. MA6348. Fermentation, isolation and structure determination.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Therapeutic uses of recombinant complement protein inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The complement system in myocardial ischaemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Induction of zymosan-air-pouch inflammation in rats and its characterization with reference to the effects of anticomplementary and anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Synthetic peptides as antagonists of the anaphylatoxin C3a

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

A comparison of the properties of two classes, C4A and C4B, of the human complement component C4

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The role of complement in experimental bullous pemphigoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Differences in altered expression of L-selectin and Mac-1 in monocytes and neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The lectin pathway of the complement system

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

A complement inhibitor produced by Stachybotrys complementi, nov. sp. K-76, a new species of fungi imperfecti

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Solution structure of Compstatin, a potent complement inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Structure of human factor D. A complement system protein at 2.0 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Selective regulation of expression of surface adhesion molecules Mac-1, L-selectin, and VLA-4 on human eosinophils and neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

C1-inhibitor concentrate for sepsis-related capillary leak syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Pharmacological characterization of antagonists of the C5a receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Cyclic disulfide analogues of the complement component C3a. Synthesis and conformational investigations

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The effect of soluble complement receptor type 1 on hyperacute allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The effect of soluble complement receptor type 1 on hyperacute xenograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Immune complex glomerulonephritis in C4- and C3-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Mammalian lectins in activation and clearance mechanisms involving the complement system

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The Regulation of Complement Activity by Pharmacologic Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Complement activation by beta-amyloid in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Complement activation in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Therapeutic intervention with complement and beta-glucan in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Tyrosine is a potential site for covalent attachment of activated complement component C3.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

C5a-mediated release of interleukin 6 by human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Hereditary angioedema: its diagnostic and management perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Effect of the sugar chain of soluble recombinant CD59 on complement inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The Arthus reaction in rodents: species-specific requirement of complement

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Degranulation from human eosinophils stimulated with C3a and C5a

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Complement depletion affects demyelination and inflammation in experimental allergic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Structure, function and cellular expression of complement anaphylatoxin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Intestinal reperfusion injury is mediated by IgM and complement

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Inhibition of Terminal Complement Complex Formation and Cell Lysis by Monoclonal Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Complement partially mediates acid aspiration-induced remote organ injury in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2980299-4

7 January 2021

10.1016/S0162-3109(00)80299-4

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10904113